At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 19 enrolled
Drug / intervention
BCX7353 capsules +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Two Dose Levels of BCX7353 as an Oral Treatment for the Prevention of Attacks in Subjects With Hereditary Angioedema
In Brief
A Phase 3 clinical trial evaluating BCX7353 capsules and Placebo oral capsule for Hereditary Angioedema, HAE. Completed, enrolled 19 participants across 10 sites.
Detailed Summary
This is a phase 3, multi-center, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of oral BCX7353 in preventing acute angioedema attacks in patients with Type I and Type II HAE who live in Japan.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHereditary Angioedema, HAE
CountriesJapan
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartDec 2018
First PostedMar 2019
Primary CompletionJul 2021
TodayJul 2026
First PostedMar 13, 2019
Enrollment StartDec 27, 2018
Primary CompletionJul 8, 2021
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 7.3 years ago
Interventions
BCX7353 capsulesdrug
BCX7353 capsules administered orally once daily
BCX7353 capsulesdrug
BCX7353 capsules administered orally once daily
Placebo oral capsuledrug
Matching placebo capsules administered orally once daily